Pentavalent vaccine provides protection to a child from 5 life-threatening diseases – Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib.
Read also: Aurobindo Pharma arm, Hilleman Labs Singapore ink pact for paediatric pentavalent vaccine
"Please note that Auro Vaccines Private Limited is not a material subsidiary to the Company and the termination of a Licence Agreement for a very early-stage vaccine asset is not a material event. It may also be noted that this termination of Agreement will not have any significant impact on the Company and/or its subsidiaries or its financials. In the event of any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures," Aurobindo noted in a BSE filing.
Medical Dialogues team had earlier reported that the European Commission (EC) has granted marketing authorization in the European Union (EU) for Zefylti, a filgrastim biosimilar, to CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma.
Earlier in December 2024, the Committee for Medicinal Products (CHMP) of EuropeanMedicines Agency has adopted positive opinion recommending the approval of Zefylti.
Read also: Aurobindo Pharma to Begin European Supply from China Facility in April
Auro Vaccines LLC is a clinical-stage vaccine development company. The Company's goal is the development and commercialization of safe and highly effective vaccines to treat and prevent viral diseases, and transformational oncolytic vaccines that unleash the body’s own immune system to attack cancer. It focuses on major and emerging infectious diseases of public health and biodefense importance and advanced-stage cancers that are not adequately addressed using current approaches.
Read also: Aurobindo Pharma to acquire 26 percent stake in solar energy company
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.